Local Institution - 124

New York, New York 10065

0 studies enrolling now · 2 studies all time

What they study most

Multiple Myeloma, Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis

Studies at this site

• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib — Stopped early
• A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) — Completed